Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/17986
Title: Shear-sensitive nanocapsule drug release for site-specific inhibition of occlusive thrombus formation.
Authors: Molloy, C P;Yao, Y;Kammoun, H;Bonnard, T;Hoefer, T;Alt, K;Tovar-Lopez, F;Rosengarten, G;Ramsland, Paul A;van der Meer, A D;van den Berg, A;Murphy, A J;Hagemeyer, C E;Peter, K;Westein, E
Affiliation: Atherothrombosis and Vascular Biology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
Haematopoiesis and Leukocyte Biology, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia
Nano Biotechnology Laboratory, Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia
School of Engineering, RMIT University, Melbourne, Victoria, Australia
School of Science, RMIT University, Bundoora, Victoria, Australia
Centre for Biomedical Research, Burnet Institute, Melbourne, Victoria, Australia
Department of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Department of Immunology, Monash University, Melbourne, Victoria, Australia
MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, the Netherlands
Issue Date: May-2017
EDate: 2017-04-09
Citation: Journal of thrombosis and haemostasis : JTH 2017; 15(5): 972-982
Abstract: Essentials Vessel stenosis due to large thrombus formation increases local shear 1-2 orders of magnitude. High shear at stenotic sites was exploited to trigger eptifibatide release from nanocapsules. Local delivery of eptifibatide prevented vessel occlusion without increased tail bleeding times. Local nanocapsule delivery of eptifibatide may be safer than systemic antiplatelet therapies. Background Myocardial infarction and stroke remain the leading causes of mortality and morbidity. The major limitation of current antiplatelet therapy is that the effective concentrations are limited because of bleeding complications. Targeted delivery of antiplatelet drug to sites of thrombosis would overcome these limitations. Objectives Here, we have exploited a key biomechanical feature specific to thrombosis, i.e. significantly increased blood shear stress resulting from a reduction in the lumen of the vessel, to achieve site-directed delivery of the clinically used antiplatelet agent eptifibatide by using shear-sensitive phosphatidylcholine (PC)-based nanocapsules. Methods PC-based nanocapsules (2.8 × 1012 ) with high-dose encapsulated eptifibatide were introduced into microfluidic blood perfusion assays and into in vivo models of thrombosis and tail bleeding. Results Shear-triggered nanocapsule delivery of eptifibatide inhibited in vitro thrombus formation selectively under stenotic and high shear flow conditions above a shear rate of 1000 s-1 while leaving thrombus formation under physiologic shear rates unaffected. Thrombosis was effectively prevented in in vivo models of vessel wall damage. Importantly, mice infused with shear-sensitive antiplatelet nanocapsules did not show prolonged bleeding times. Conclusions Targeted delivery of eptifibatide by shear-sensitive nanocapsules offers site-specific antiplatelet potential, and may form a basis for developing more potent and safer antiplatelet drugs.
URI: http://ahro.austin.org.au/austinjspui/handle/1/17986
DOI: 10.1111/jth.13666
PubMed URL: 28267256
Type: Journal Article
Research Support, Non-U.S. Gov't
Subjects: antiplatelet drugs
drug delivery systems
microfluidics
nanocapsules
platelets
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.